THE INNOVATIVE MEDICINES INITIATIVE
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.
IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
IMI enters new phase with €3.3 billion budget
IMI enters its second phase with a €3.3 billion budget & the ambitious goal of fast-tracking the development of the next generation of medicines, especially in areas of unmet need.
- 28/07/2014 : RT @EU_Health: Today is #WorldHepatitisDay Campaign materials, facts and figures here http://t.co/Rchp9ddn7b #ThinkHepatitis via @WHO
- 28/07/2014 : RT @gray_alasdair: The @Open_PHACTS Chemistry Lenses paper has been accepted on the @iswc2014 in-use track http://t.co/aNR9iXofWU
- 24/07/2014 : Places on our 3 Sept webinar on #IMI2 rules & procedures are filling up fast! Save your spot at http://t.co/nsg0VzYPXC